CCXAP upgrades Taizhou Huaxin Pharmaceutical Investment Co., Ltd.’s long-term credit rating to BBBg+, with stable outlook | News & Events | China Chengxin (Asia Pacific) Credit Ratings Company Limited

2024.6.13

CCXAP upgrades Taizhou Huaxin Pharmaceutical Investment Co., Ltd.’s long-term credit rating to BBBg+, with stable outlook

Hong Kong, 13 June 2024 -- China Chengxin (Asia Pacific) Credit Ratings Company Limited (“CCXAP”) has upgraded Taizhou Huaxin Pharmaceutical Investment Co., Ltd.’s (“Huaxin” or the “Company”) long-term credit rating from BBB_g to BBB_g+, with stable outlook, reflecting the improved comprehensive strength of Taizhou City, the good development prospect of Taizhou Medical High-Tech Industrial Development Zone (Gaogang Zone) (“Taizhou Medical Zone”), and Huaxin's good track record of receiving government supports.

Click HERE to download the press release.

CCXAP’s public ratings are available at www.ccxap.com (Rating Results) and may be distributed through media and other means. Methodology used in this rating is the Rating Methodology for China’s Local Infrastructure Investment and Financing Companies dated July 2022, available at www.ccxap.com (Rating Methodologies).